MA27054A1 - Formulation de suspension orale stabilisee - Google Patents
Formulation de suspension orale stabiliseeInfo
- Publication number
- MA27054A1 MA27054A1 MA27503A MA27503A MA27054A1 MA 27054 A1 MA27054 A1 MA 27054A1 MA 27503 A MA27503 A MA 27503A MA 27503 A MA27503 A MA 27503A MA 27054 A1 MA27054 A1 MA 27054A1
- Authority
- MA
- Morocco
- Prior art keywords
- oral suspension
- stabilized oral
- suspension formulation
- thixotropic
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Abstract
DEPOSANT Société dite: PHARMACIA CORPORATION REVENDICATIONS DE PRIORITES US 6 Août 2001 60/310,372 Voir en annexe le titre de l'invention et le texte de l'abrégé Formulation de suspension orale stabilisée Il est proposé des compositions pharmaceutiques pouvant être administrées par voie orale, comprenant un médicament à faible hydrosolubilité en suspension dans un véhicule liquide aqueux comprenant un agent mouillant, un agent épaississant thixotrope et un agent inorganique de mise en suspension. Les compositions sont thixotrope, substantiellement défloculées, et substantiellement stables physiquement.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31037201P | 2001-08-06 | 2001-08-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27054A1 true MA27054A1 (fr) | 2004-12-20 |
Family
ID=23202195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA27503A MA27054A1 (fr) | 2001-08-06 | 2004-01-27 | Formulation de suspension orale stabilisee |
Country Status (34)
Country | Link |
---|---|
US (2) | US20030108575A1 (fr) |
EP (1) | EP1414409B1 (fr) |
JP (1) | JP2005500363A (fr) |
KR (1) | KR20040025740A (fr) |
CN (1) | CN1287768C (fr) |
AP (1) | AP1817A (fr) |
AT (1) | ATE353627T1 (fr) |
BR (1) | BR0211736A (fr) |
CA (1) | CA2454173A1 (fr) |
CO (1) | CO5560559A2 (fr) |
CY (1) | CY1106548T1 (fr) |
DE (1) | DE60218175T2 (fr) |
DK (1) | DK1414409T3 (fr) |
EA (1) | EA007901B1 (fr) |
EC (1) | ECSP044974A (fr) |
ES (1) | ES2280560T3 (fr) |
GE (1) | GEP20074027B (fr) |
HK (1) | HK1069542A1 (fr) |
HR (1) | HRP20040118A2 (fr) |
IL (1) | IL159551A0 (fr) |
IS (1) | IS7126A (fr) |
MA (1) | MA27054A1 (fr) |
MX (1) | MXPA04001109A (fr) |
MY (1) | MY135119A (fr) |
NZ (1) | NZ530844A (fr) |
OA (1) | OA12646A (fr) |
PL (1) | PL366382A1 (fr) |
PT (1) | PT1414409E (fr) |
SI (1) | SI1414409T1 (fr) |
TN (1) | TNSN04023A1 (fr) |
UA (1) | UA80682C2 (fr) |
WO (1) | WO2003013473A1 (fr) |
YU (1) | YU7404A (fr) |
ZA (1) | ZA200400639B (fr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9720061D0 (en) | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
US20040105889A1 (en) * | 2002-12-03 | 2004-06-03 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
US9101540B2 (en) | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
US20050036956A1 (en) * | 2003-08-15 | 2005-02-17 | Lin Fei | Non-aqueous liquid tooth whitening composition |
TR200301552A1 (tr) * | 2003-09-18 | 2005-10-21 | Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. | Rofekoksib' in yeni oral farmakolojik formülasyonları. |
US20050266031A1 (en) * | 2004-05-25 | 2005-12-01 | Jay Dickerson | Pharmaceutical suspension composition |
US8318210B2 (en) | 2005-02-28 | 2012-11-27 | Neos Therapeutics, Lp | Compositions and methods of making sustained release liquid formulations |
US8653145B2 (en) * | 2005-09-22 | 2014-02-18 | Eaton Scientific Systems, Ltd. | Method for alleviating climacteric symptoms |
MY157620A (en) | 2006-01-31 | 2016-06-30 | Cytochroma Dev Inc | A granular material of a solid water-soluble mixed metal compound capable of binding phosphate |
DK2018153T3 (da) | 2006-04-26 | 2012-07-23 | Rosemont Pharmaceuticals Ltd | Flydende orale sammensætninger |
CN100434072C (zh) * | 2006-06-19 | 2008-11-19 | 西安交通大学 | 具有抗炎性作用及改善血液流变性和抑制血栓形成的药物 |
GB0714670D0 (en) | 2007-07-27 | 2007-09-05 | Ineos Healthcare Ltd | Use |
GB0720220D0 (en) | 2007-10-16 | 2007-11-28 | Ineos Healthcare Ltd | Compound |
WO2009133431A1 (fr) * | 2008-04-30 | 2009-11-05 | Wockhardt Research Centre | Compositions liquides orales de rhéine ou de diacéréine |
GB0913525D0 (en) | 2009-08-03 | 2009-09-16 | Ineos Healthcare Ltd | Method |
GB201001779D0 (en) | 2010-02-04 | 2010-03-24 | Ineos Healthcare Ltd | Composition |
WO2011107855A2 (fr) | 2010-03-04 | 2011-09-09 | Torrent Pharmaceuticals Limited | Forme dosifiée sous forme de suspension liquide à libération prolongée pour une administration par voie orale |
PL2544532T3 (pl) | 2010-03-12 | 2017-08-31 | Monsanto Technology Llc | Agrochemiczne kompozycje żelowe |
DK2575784T3 (en) * | 2010-06-02 | 2018-10-15 | Astellas Deutschland Gmbh | ORAL DOSAGE FORMS OF BENDAMUSTIN |
EP2462922A1 (fr) * | 2010-12-10 | 2012-06-13 | Bioprojet | Nouvelle forme d'administration pour inhibiteurs de l'enképhalinase |
WO2012099142A1 (fr) * | 2011-01-18 | 2012-07-26 | 千寿製薬株式会社 | Composition liquide aqueuse de bromfénac qui est efficace comme conservateur |
KR102237799B1 (ko) | 2012-11-14 | 2021-04-08 | 더블유.알. 그레이스 앤드 캄파니-콘. | 생물학적 활성 물질 및 비-정렬된 무기 산화물을 함유하는 조성물 |
JP2018516279A (ja) * | 2015-05-29 | 2018-06-21 | コーダドース・インコーポレーテッド | 経口投与用のセレコキシブの液状配合物 |
US11083780B2 (en) | 2015-07-20 | 2021-08-10 | The Brigham And Women's Hospital, Inc. | Shear-thinning compositions as an intravascular embolic agent |
CN105902409B (zh) * | 2016-05-13 | 2019-03-05 | 广东龙湖科技股份有限公司 | 一种温和且具有触变性的牙膏 |
CN109843331A (zh) * | 2016-10-19 | 2019-06-04 | 萨恩帕斯药物有限公司 | Dmpc、dmpg、dmpc/dmpg、lysopg和lysopc针对引起离子通道病的药物的保护作用 |
WO2019070818A2 (fr) * | 2017-10-04 | 2019-04-11 | Panacea Biomatx, Inc. | Suspensions de produits pharmaceutiques encapsulés et leurs procédés de fabrication et d'utilisation |
CN112402376A (zh) * | 2019-08-22 | 2021-02-26 | 上海上药信谊药厂有限公司 | 一种结肠靶向的柳氮磺吡啶口服混悬剂及其制备方法 |
CN117883379A (zh) * | 2021-02-12 | 2024-04-16 | 浙江贝灵生物医药有限公司 | 一种口服碱性溶媒组合物及其制备方法与应用 |
WO2022185338A1 (fr) * | 2021-03-05 | 2022-09-09 | Alkem Laboratories Limited | Suspension orale stable de célécoxib et son procédé de préparation |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4684666A (en) * | 1986-08-19 | 1987-08-04 | Haas Pharmaceuticals, Inc. | Stabilized liquid analgesic compositions |
KR920702616A (ko) * | 1989-06-13 | 1992-10-06 | 원본미기재 | 약제를 전달하기 위한 무수 오일-기제된 액체 현탁액 |
US5112604A (en) * | 1989-09-01 | 1992-05-12 | Riker Laboratories, Inc. | Oral suspension formulation |
US5616458A (en) * | 1990-03-14 | 1997-04-01 | Board Of Regents, University Of Tx System | Tripterygium wilfordii hook F extracts and components, and uses thereof |
US5604260A (en) * | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
US5543297A (en) * | 1992-12-22 | 1996-08-06 | Merck Frosst Canada, Inc. | Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity |
US5380738A (en) * | 1993-05-21 | 1995-01-10 | Monsanto Company | 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents |
US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5436265A (en) * | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
US5593992A (en) * | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
US5344991A (en) * | 1993-10-29 | 1994-09-06 | G.D. Searle & Co. | 1,2 diarylcyclopentenyl compounds for the treatment of inflammation |
US5475018A (en) * | 1993-11-30 | 1995-12-12 | G. D. Searle & Co. | 1,5-diphenyl pyrazole compounds for treatment of inflammation |
US5401765A (en) * | 1993-11-30 | 1995-03-28 | G. D. Searle | 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders |
US5434178A (en) * | 1993-11-30 | 1995-07-18 | G.D. Searle & Co. | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation |
CA2276945C (fr) * | 1993-11-30 | 2006-08-01 | G.D. Searle & Co. | Pyrazolyle benzenesulfonamide tricyclique-substitue et leurs compositions pharmaceutiques |
US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
US5393790A (en) * | 1994-02-10 | 1995-02-28 | G.D. Searle & Co. | Substituted spiro compounds for the treatment of inflammation |
AU2424895A (en) * | 1994-05-04 | 1995-11-29 | G.D. Searle & Co. | Substituted spirodienes for the treatment of inflammation |
US5418254A (en) * | 1994-05-04 | 1995-05-23 | G. D. Searle & Co. | Substituted cyclopentadienyl compounds for the treatment of inflammation |
US5486534A (en) * | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
EP1125932A3 (fr) * | 1994-07-27 | 2001-08-29 | G.D. Searle & Co. | Thiazoles substitués destinés au traitement de l'inflammation |
US5620999A (en) * | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
US5616601A (en) * | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5521213A (en) * | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
US5420343A (en) * | 1994-08-31 | 1995-05-30 | G. D. Searle & Co. | Derivatives of aromatic cyclic alkylethers |
US5585504A (en) * | 1994-09-16 | 1996-12-17 | Merck & Co., Inc. | Process of making cox-2 inhibitors having a lactone bridge |
US5696143A (en) * | 1994-09-20 | 1997-12-09 | Talley; John J. | Benz G! indazolyl derivatives for the treatment of inflammation |
US5547975A (en) * | 1994-09-20 | 1996-08-20 | Talley; John J. | Benzopyranopyrazolyl derivatives for the treatment of inflammation |
ES2139959T3 (es) * | 1994-10-27 | 2000-02-16 | Merck Frosst Canada Inc | Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2. |
US5739166A (en) * | 1994-11-29 | 1998-04-14 | G.D. Searle & Co. | Substituted terphenyl compounds for the treatment of inflammation |
JP3181190B2 (ja) * | 1994-12-20 | 2001-07-03 | 日本たばこ産業株式会社 | オキサゾール誘導体 |
JP2636819B2 (ja) * | 1994-12-20 | 1997-07-30 | 日本たばこ産業株式会社 | オキサゾール系複素環式芳香族化合物 |
US5552422A (en) * | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
CA2211320C (fr) * | 1995-01-31 | 2007-03-20 | Merck Frosst Canada Inc. | 5-methanesulfonamido-3h-isobenzofuran-1-ones utilises comme inhibiteurs de cyclooxygenase-2 |
US5686470A (en) * | 1995-02-10 | 1997-11-11 | Weier; Richard M. | 2, 3-substituted pyridines for the treatment of inflammation |
US5596008A (en) * | 1995-02-10 | 1997-01-21 | G. D. Searle & Co. | 3,4-Diaryl substituted pyridines for the treatment of inflammation |
US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
US5639780A (en) * | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
US5604253A (en) * | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
US5510368A (en) * | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
CN1174970C (zh) * | 1995-05-25 | 2004-11-10 | G·D·瑟尔公司 | 3-卤代烷基-1h-吡唑的制备方法 |
US5643933A (en) * | 1995-06-02 | 1997-07-01 | G. D. Searle & Co. | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
US5658903A (en) * | 1995-06-07 | 1997-08-19 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
US5739143A (en) * | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
GB9514518D0 (en) * | 1995-07-15 | 1995-09-13 | Sod Conseils Rech Applic | Guanidine salt inhibitors of NO synthase and cyclooxygenase |
JPH0977664A (ja) * | 1995-09-13 | 1997-03-25 | Yakult Honsha Co Ltd | シクロオキシゲナーゼ−2特異的阻害剤及び抗炎症剤 |
US5756529A (en) * | 1995-09-29 | 1998-05-26 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies |
US6020343A (en) * | 1995-10-13 | 2000-02-01 | Merck Frosst Canada, Inc. | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors |
US5981576A (en) * | 1995-10-13 | 1999-11-09 | Merck Frosst Canada, Inc. | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors |
US6057319A (en) * | 1995-10-30 | 2000-05-02 | Merck Frosst Canada & Co. | 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors |
US6046208A (en) * | 1996-01-11 | 2000-04-04 | Smithkline Beecham Corporation | Substituted imidazole compounds |
NZ327044A (en) * | 1996-01-11 | 2000-01-28 | Smithkline Beecham Corp | Substituted imidazole compounds |
ZA97175B (en) * | 1996-01-11 | 1997-11-04 | Smithkline Beecham Corp | Novel substituted imidazole compounds. |
US5789413A (en) * | 1996-02-01 | 1998-08-04 | Merck Frosst Canada, Inc. | Alkylated styrenes as prodrugs to COX-2 inhibitors |
GB9607503D0 (en) * | 1996-04-11 | 1996-06-12 | Merck Frosst Canada Inc | Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors |
US5807873A (en) * | 1996-04-04 | 1998-09-15 | Laboratories Upsa | Diarylmethylidenefuran derivatives and their uses in therapeutics |
DE69739003D1 (de) * | 1996-04-12 | 2008-10-30 | Searle Llc | Substituierte Benzensulfonamid-Derivate als Wirkstoff-Vorläufer von COX-2 Inhibitoren |
US5922742A (en) * | 1996-04-23 | 1999-07-13 | Merck Frosst Canada | Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors |
US5883267A (en) * | 1996-05-31 | 1999-03-16 | Merck & Co., Inc. | Process for making phenyl heterocycles useful as cox-2 inhibitors |
US5741798A (en) * | 1996-06-03 | 1998-04-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | 2-benzyl-4-sulfonyl-4H-isoquinolin-1,3-diones and their use as antiinflammatory agents |
US5677318A (en) * | 1996-07-11 | 1997-10-14 | Merck Frosst Canada, Inc. | Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents |
US5861419A (en) * | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
US5776967A (en) * | 1996-07-26 | 1998-07-07 | American Home Products Corporation | Pyranoindole inhibitors of COX--2 |
FR2751964B1 (fr) * | 1996-08-01 | 1998-10-30 | Union Pharma Scient Appl | Nouveaux derives diarylmethylene carbocycliques, leurs procedes de preparation, et leurs utilisations en therapeutique |
FR2751966B1 (fr) * | 1996-08-01 | 1998-10-30 | Union Pharma Scient Appl | Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique |
US5830911A (en) * | 1996-08-14 | 1998-11-03 | American Home Products Corporation | Pyranoindole and tetrahydrocarbazole inhibitors of COX-2 |
US6005000A (en) * | 1996-08-22 | 1999-12-21 | Oxis International, Inc. | 5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor |
FR2753449B1 (fr) * | 1996-09-13 | 1998-12-04 | Union Pharma Scient Appl | Nouveaux derives 3,4-diaryloxazolone, leurs procedes de preparation, et leurs utilisations en therapeutique |
US5972950A (en) * | 1996-10-08 | 1999-10-26 | Laboratories Upsa | 1,2-diarylmethylene derivatives, their methods of preparation and their uses in therapeutics |
US5681842A (en) * | 1996-11-08 | 1997-10-28 | Abbott Laboratories | Prostaglandin synthase-2 inhibitors |
US5869524A (en) * | 1996-11-12 | 1999-02-09 | American Home Products Corporation | Indene inhibitors of COX-2 |
US6096753A (en) * | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
ATE250576T1 (de) * | 1996-12-10 | 2003-10-15 | Searle & Co | Substituierte pyrrolylverbindungen zur behandlung von entzündungen |
US5973191A (en) * | 1996-12-30 | 1999-10-26 | Vanderbilt University | Selective inhibitors of prostaglandin endoperoxide synthase-2 |
US5929076A (en) * | 1997-01-10 | 1999-07-27 | Smithkline Beecham Corporation | Cycloalkyl substituted imidazoles |
US5783597A (en) * | 1997-03-04 | 1998-07-21 | Ortho Pharmaceutical Corporation | 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use |
US6004960A (en) * | 1997-03-14 | 1999-12-21 | Merck Frosst Canada, Inc. | Pyridazinones as inhibitors of cyclooxygenase-2 |
US6071954A (en) * | 1997-03-14 | 2000-06-06 | Merk Frosst Canada, Inc. | (methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors |
US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
US6046217A (en) * | 1997-09-12 | 2000-04-04 | Merck Frosst Canada & Co. | 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2 |
US6040450A (en) * | 1997-09-25 | 2000-03-21 | Merck & Co., Inc. | Process for making diaryl pyridines useful as cox-2-inhibitors |
FR2769311B1 (fr) * | 1997-10-07 | 1999-12-24 | Union Pharma Scient Appl | Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique |
US6133292A (en) * | 1997-10-30 | 2000-10-17 | Merck Frosst Canada & Co. | Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors |
US6020347A (en) * | 1997-11-18 | 2000-02-01 | Merck & Co., Inc. | 4-substituted-4-piperidine carboxamide derivatives |
FR2771412B1 (fr) * | 1997-11-26 | 2000-04-28 | Adir | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
PT1071745E (pt) * | 1998-04-24 | 2004-11-30 | Merck & Co Inc | Processo para sintetizar inibidores cox-2 |
US6077869A (en) * | 1998-10-29 | 2000-06-20 | Ortho-Mcneil Pharmaceutical, Inc. | Aryl phenylhydrazides as selective COX-2 inhibitors for treatment of inflammation |
SA99191255B1 (ar) * | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
US6077868A (en) * | 1999-07-20 | 2000-06-20 | Wisconsin Alumni Research Foundation | Selective inhibition of cyclooxygenase-2 |
US6083969A (en) * | 1999-10-20 | 2000-07-04 | Ortho-Mcneil Pharaceutical, Inc. | 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents |
WO2001030342A1 (fr) * | 1999-10-20 | 2001-05-03 | Board Of Trustees Of Southern Illinois University | Utilisation des flavones comme inhibiteurs de l'oxyde nitrique synthase inductibles, comme inhibiteurs de cyclooxygenase-2 et comme activateurs des canaux potassiques |
ES2236007T3 (es) * | 1999-12-08 | 2005-07-16 | Pharmacia Corporation | Composiciones de inhibidor de ciclooxigenasa-2 ue tiene un efecto terapeutico rapido. |
CA2406226A1 (fr) * | 2000-04-18 | 2001-10-25 | Pharmacia Corporation | Formulation a effet therapeutique rapide contenant un inhibiteur selectif de la cyclooxygenase-2 |
WO2002005799A2 (fr) * | 2000-07-13 | 2002-01-24 | Pharmacia Corporation | Composes vasomodulateurs et inhibiteurs selectifs de la cyclo-oxygenase-2 pour le traitement des douleurs generalisees et des cephalees |
GB0617119D0 (en) * | 2006-08-31 | 2006-10-11 | Renovo Ltd | Method of prognosis |
-
2002
- 2002-05-08 UA UA2004020879A patent/UA80682C2/uk unknown
- 2002-08-05 DE DE60218175T patent/DE60218175T2/de not_active Expired - Fee Related
- 2002-08-05 CN CNB02815522XA patent/CN1287768C/zh not_active Expired - Fee Related
- 2002-08-05 KR KR10-2004-7001860A patent/KR20040025740A/ko not_active Application Discontinuation
- 2002-08-05 AP APAP/P/2004/002969A patent/AP1817A/en active
- 2002-08-05 BR BR0211736-3A patent/BR0211736A/pt not_active IP Right Cessation
- 2002-08-05 WO PCT/US2002/024746 patent/WO2003013473A1/fr active IP Right Grant
- 2002-08-05 PL PL02366382A patent/PL366382A1/xx not_active Application Discontinuation
- 2002-08-05 CA CA002454173A patent/CA2454173A1/fr not_active Abandoned
- 2002-08-05 OA OA1200400030A patent/OA12646A/en unknown
- 2002-08-05 IL IL15955102A patent/IL159551A0/xx unknown
- 2002-08-05 AT AT02756952T patent/ATE353627T1/de not_active IP Right Cessation
- 2002-08-05 US US10/212,308 patent/US20030108575A1/en not_active Abandoned
- 2002-08-05 SI SI200230516T patent/SI1414409T1/sl unknown
- 2002-08-05 YU YU7404A patent/YU7404A/sh unknown
- 2002-08-05 EA EA200400148A patent/EA007901B1/ru not_active IP Right Cessation
- 2002-08-05 EP EP02756952A patent/EP1414409B1/fr not_active Expired - Lifetime
- 2002-08-05 MX MXPA04001109A patent/MXPA04001109A/es active IP Right Grant
- 2002-08-05 PT PT02756952T patent/PT1414409E/pt unknown
- 2002-08-05 DK DK02756952T patent/DK1414409T3/da active
- 2002-08-05 GE GE5420A patent/GEP20074027B/en unknown
- 2002-08-05 NZ NZ530844A patent/NZ530844A/en unknown
- 2002-08-05 ES ES02756952T patent/ES2280560T3/es not_active Expired - Lifetime
- 2002-08-05 JP JP2003518483A patent/JP2005500363A/ja active Pending
- 2002-08-06 MY MYPI20022925A patent/MY135119A/en unknown
-
2004
- 2004-01-26 IS IS7126A patent/IS7126A/is unknown
- 2004-01-27 MA MA27503A patent/MA27054A1/fr unknown
- 2004-01-27 ZA ZA200400639A patent/ZA200400639B/en unknown
- 2004-02-03 HR HR20040118A patent/HRP20040118A2/hr not_active Application Discontinuation
- 2004-02-05 TN TNP2004000023A patent/TNSN04023A1/fr unknown
- 2004-02-06 CO CO04009302A patent/CO5560559A2/es not_active Application Discontinuation
- 2004-02-06 EC EC2004004974A patent/ECSP044974A/es unknown
-
2005
- 2005-03-14 HK HK05102202A patent/HK1069542A1/xx not_active IP Right Cessation
-
2007
- 2007-04-26 CY CY20071100568T patent/CY1106548T1/el unknown
- 2007-12-21 US US11/962,903 patent/US20090081309A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27054A1 (fr) | Formulation de suspension orale stabilisee | |
HUP0203028A2 (hu) | Tolterodint tartalmazó gyógyszerkészítmény és alkalmazása | |
HRP20030951B1 (hr) | Formulacije jednodnevnih doza oksikodona | |
MA26859A1 (fr) | Forme posologique de medicament commandée par un hydrogel. | |
FR2830447B1 (fr) | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques | |
HRP20030910A2 (en) | Tartarate salts 5,8,14-triazatetracyclo {10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>}-hexadeca-2(11), 3,5,7,9-pentaene and pharmaceutical compositions thereof | |
BR0013157A (pt) | Composições farmacêuticas e nutricionais contendo ácidos graxos essenciais e agentes de abaixamento da homocisteìna | |
WO2007067593A3 (fr) | Formulations d'inhibiteur de cetp | |
PL1620392T3 (pl) | Oksymowe pochodne hydroksy-bifenylo-karbaldehydu i ich zastosowania jako środków estrogennych | |
FR2808685B1 (fr) | Compositions pharmaceutiques pour administration transdermique d'agents anti-inflammatoires | |
DE60121857D1 (de) | Arzneimittelzusammensetzung mit verzögerter Wirkstoffabgabe | |
MXPA05008909A (es) | Formulacion intranasal de rotigotina. | |
EP1993567A4 (fr) | Préparations de gallium administrables per os et leurs méthodes d'utilisation | |
ITMI20021392A1 (it) | Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita' | |
DK1104289T3 (da) | Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister | |
RS50089B (sr) | Suspenzija ziprasidona | |
ES2130081B1 (es) | Comprimido de maleato de trimebutina con recubrimiento laminar. | |
HUP0304085A3 (en) | The citrate salt of 5,8,14-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof | |
MY138172A (en) | Pharmaceutical compositions based on azetidine derivatives | |
MXPA03005221A (es) | Composicion farmaceutica de dronedarona para administracion parenteral. | |
WO2004069187A3 (fr) | Formulation et administration d'un medicament a l'aide de cyclodextrines cristallines methylees | |
DK1653923T3 (da) | Oral afleveringssystem omfattende en bivæsket skum | |
BR0206960A (pt) | Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose | |
AP2001002119A0 (en) | Sertraline oral concentrate. | |
BR0011845A (pt) | Complexo farmacêutico |